High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2211-2218

  Leebeek, Frank W G ^a   Van Goor, M P J ^a   Guimaraes, A H C ^a,b   Brouwers, G J ^a   De Maat, M P M ^a   Dippel, D W J ^a   Rijken, D C ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Fibrinolysis; Gene polymorphisms; Ischemic stroke; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

CARBOXYPEPTIDASE; POTATO CARBOXYPEPTIDASE INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FIBRINOLYSIS; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; BRAIN ISCHEMIA; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; EPIDEMIOLOGY, MOLECULAR; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBRINOLYSIS; GENOTYPE; HUMANS; KINETICS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK;

EID: 28444480174     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01484.x     Document Type: Article

References (27)

1. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the anti-fibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
2. Wang W, Boffa PB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 176-81.
3. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
4. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.
5. Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P. Association between TAFI antigen and Ala 147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89: 554-60.
6. Brouwers GJ, Leebeek FWG, Tanck MWT, Jukema JW, Kluft C, de Maat MPM. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
7. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
8. Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, Lourenco DM, Morelli VM, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
9. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3′-region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
10. Brouwers GJ, Vos HL, Leebeek FW, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-3.
11. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-91.
12. Montaner J, Ribo M, Moasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-40.
13. Bamford J, Sandercock P, Dennis M, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
14. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, and the TOAST Investigators. Classification of subtype of acute ischemic stroke. Stroke 1993; 24: 35-41.
15. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965; 14: 61-5.
16. Guimaraes AHC, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor (TAFI). J Thromb Haemost 2005; 3: 1284-92.
17. Tanck MW, Klerkx AH, Jukema JW, De Knijff P, Kastelein JJ, Zwinderman AH. Estimation of multilocus haplotype effects using weighted penalised log-likelihood: analysis of five sequence variations at the cholesteryl ester transfer protein gene locus. Ann Hum Genet 2003; 67: 175-84.
18. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-8.
19. Catto AJ, Carter AM, Strickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
20. Gils A, Alessi M-C, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, DeClerck PJ. Development of a genotype 325 specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
21. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
22. Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, Aznar J, Estelles A. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-65.
23. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
24. Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade in human plasma. Clin Chem 1999; 45: 807-13.
25. Lisman T, Leebeek FWG, Mosnier LO, Bouma BN, Meijers JCM, Janssen HLA, Nieuwenhuis HK, de Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
26. van Goor ML, Gomez Garcia E, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost 2005; 93: 92-6.
27. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamaria E, Quintana M, Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35: 2123-7.